Dexcom Inc(DXCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | NDX, S&P 500 | P/E | 33.12 | EPS (ttm) | 2.53 | Insider Own | 1.78% | Shs Outstand | 377.4M | Perf Week | -6.91% |
| Market Cap | 31.66B | Forward P/E | 26.89 | EPS next Y | 16.98% | Insider Trans | -2.04% | Shs Float | 370.6M | Perf Month | -4.27% |
| Enterprise Value | 31.11B | PEG | 1.27 | EPS next Q | 0.67 | Inst Own | 105.07% | Short Float | 4.46% | Perf Quarter | 7.31% |
| Income | 1.00B | P/S | 6.37 | EPS this Y | 27.63% | Inst Trans | 1.16% | Short Ratio | 3.44 | Perf Half Y | 23.78% |
| Sales | 4.97B | P/B | 12.08 | EPS next 5Y | 21.18% | ROA | 14.51% | Short Interest | 16.53M | Perf YTD | 26.42% |
| Book/sh | 6.95 | P/C | 16.26 | EPS past 3/5Y | 37.83% 10.55% | ROE | 38.49% | 52W High | -9.38% ($92.59) | Perf Year | 7.03% |
| Cash/sh | 5.16 | P/FCF | 22.54 | Sales past 3/5Y | 17.01% 19.33% | ROIC | 25% | 52W Low | 55.07% ($54.11) | Perf 3Y | -19.59% |
| Dividend Est. | - | EV/EBITDA | 22.17 | EPS Y/Y TTM | 77.43% | Gross Margin | 63.57% | Volatility(W/M) | 2.41% 2.65% | Perf 5Y | -39.27% |
| Dividend TTM | - | EV/Sales | 6.26 | Sales Y/Y TTM | 15.54% | Oper. Margin | 22.92% | ATR (14) | 2.56 | Perf 10Y | 261.05% |
| Dividend Ex-Date | - | Quick Ratio | 1.43 | EPS Q/Q | 43.63% | Profit Margin | 20.12% | RSI (14) | 42.09 | Recom | 1.42 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | Sales Q/Q | 13.08% | SMA20 | -6.2% ($89.46) | Beta | 1.48 | Target Price | $94.75 |
| Payout | - | Debt/Eq | 0.53 | Earnings | 2026/7/30 | SMA50 | 2.59% ($81.79) | Rel Volume | 0.82 | Prev Close | $84.53 |
| Employees | 11100 | LT Debt/Eq | 0.53 | EPS/Sales Surpr. | 14.59% 1.4% | SMA200 | 17.95% ($71.14) | Avg Volume(3M) | 4.81M | Price | $83.91 |
| IPO | 2005/4/14 | Option/Short | Yes/Yes | Trades | 35509 | Volume | 3,947,501 | Change | -0.74% |
Company
DXCM is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global medical device company specializing in Continuous Glucose Monitoring (CGM) systems. Founded in 1999 and headquartered in San Diego, California, USA, it is a leading large-cap medical device company that operates both prescription-based medical devices and consumer models.
Over the past 1 year, on the higher side
9% below its 1-year high.
DXCM makes money exceptionally well
22.92% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.6% this year.
Tap to view numbers
The price looks about right
Trading at 33.1 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -19.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 105.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
EKG 0.07%
TMFM 0.05%
HEAL 0.05%
SNSR 0.05%
IHI 0.04%It ranks #4 in the industry
Based on market cap of $32B.
DXCM $32B PER 33.1
ABT $182B PER 34.0
MDT $118B PER 22.6
SYK $106B PER 28.5
FAQ
What kind of company is DXCM?
DXCM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of DXCM?
The market cap of DXCM is approximately $31.7B, ranking 449 within its sector.
What is the P/E ratio of DXCM?
DXCM has a P/E ratio of approximately 33.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DXCM?
DXCM has recorded a 52-week high of $92.59 and a low of $54.11.
